In addition to hypertension, as described above, it has now been clearly demonstrated that anti-VEGF agents exhibit various cardiotoxic manifestations, including cardiac dysfunction, arterial and venous thrombosis, and QTc prolongation [79,80], and that these are some of the most challenging events for patients. Here, VEGFA is linked to deep vein thrombosis.